Leo Pharma takes hand eczema treatment into phase III
A new phase III study will investigate Leo Pharma’s drug delgocitinib as a cream for children and adolescents with severe chronic hand eczema.
by christian bundgaard, translated by daniel pedersen
After success in a phase IIb study of adult patients, Leo Pharma is now turning its attention to children and adolescents between the ages 12 and 17 in order to expand the target group for delgocitinib, according to a registration on the Clinical Trials database.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma brings hair loss cream into phase II
For subscribers
Small molecules to lead Leo Pharma to greatness
For subscribers
.jpg&w=384&q=75)
